Pharmaceuticals

BridGene Biosciences to Present at Hippo Pathway Targeted Drug Development Summit

by

SAN JOSE, Calif., May 18, 2023 /PRNewswire/ — BridGene Biosciences, Inc., a biotechnology company using a proprietary chemoproteomics technology to discover and develop small molecules for high-value, traditionally undruggable targets, announced that Wolf Wiedemeyer, Ph.D., head of biology at BridGene, will be giving a presentation, titled “A Covalent TEAD Inhibitor with Exceptional Anti-cancer Activity & … Read more

European study highlights need to improve the quality of conversations about induction of labour (IoL) in clinical settings

by

Almost 1 in 2 women (49%) felt the experience of IoL differed from their expectations The majority of expectant mothers (65%) did not feel fully involved in choosing which method of IoL they prefer Findings emphasize the importance of collaborative decision-making between healthcare professionals and expectant mothers   AMSTERDAM, May 18, 2023 /PRNewswire/ — Norgine … Read more

Projected Market Value of US$ 8177.9 billion and CAGR of 31.3%

by

According to Prophecy Market Insights “Non-Alcoholic Steatohepatitis Biomarkers Market accounted for US$ 556.6 billion in 2019 and is estimated to be US$ 8177.9 billion by 2029 and is anticipated to register a CAGR of 31.3%” COVINA, Calif., May 18, 2023 /PRNewswire/ — What is the Overview of Non-Alcoholic Steatohepatitis Biomarkers Market? Non-alcoholic steatohepatitis (NASH) is the … Read more

Women’s Health Market to Reach $63.02 Billion by 2030: Grand View Research, Inc.

by

SAN FRANCISCO, May 18, 2023 /PRNewswire/ — The global women’s health market size is expected to reach USD 63.02 billion by 2030, registering a CAGR of 5.4% from 2023 to 2030, according to a new report by Grand View Research, Inc. The introduction of innovative novel products and the presence of a strong pipeline of women’s … Read more

Asieris Deepens Strategic Partnership with UroViu to Further Develop Integrated Diagnosis and Treatment Platform for Bladder Cancer

by

SHANGHAI, May 18, 2023 /PRNewswire/ — Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced a strategic collaboration with UroViu Corporation (“UroViu”). Asieris Pharmaceuticals will obtain exclusive global rights to UroViu’s patented technology of portable single-use cystoscope in … Read more

ImaginAb Advances Two Solid Tumor Radiopharmaceutical Therapy (RPT) Candidates Towards Clinical Development

by

IAB56 RPT agent is designed to target integrin αvβ6, a receptor over-expressed in a broad range of solid cancers underserved by current cancer therapies. IAB57 RPT agent is designed to target DLL3, a target over-expressed in cancer tissues and relevant in several cancers, most notably Small-Cell Lung Cancer (SCLC) LOS ANGELES, May 18, 2023 /PRNewswire/ … Read more

ImaginAb Advances Two Solid Tumor Radiopharmaceutical Therapy (RPT) Candidates Towards Clinical Development

by

IAB56 RPT agent is designed to target integrin αvβ6, a receptor over-expressed in a broad range of solid cancers underserved by current cancer therapies. IAB57 RPT agent is designed to target DLL3, a target over-expressed in cancer tissues and relevant in several cancers, most notably Small-Cell Lung Cancer (SCLC) LOS ANGELES, May 18, 2023 /PRNewswire/ … Read more

Das in Providence ansässige “Biotech-Start-up” EpiVax feiert sein 25-jähriges Bestehen

by

PROVIDENCE, R.I., 18. Mai 2023 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) feiert seinen 25sten Geburtstag, indem das Unternehmen sein Engagement für die Verbesserung der menschlichen Gesundheit überall auf der Welt erneuert und gleichzeitig die Entwicklung bahnbrechender Instrumente durch das Unternehmen hervorhebt. Darüber hinaus würdigt EpiVax die Arbeit von zwei gemeinnützigen Organisationen, die in diesen 25 Jahren … Read more

Kapruvia® (difelikefalin) recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

by

Recommendation will enable eligible patients in England, Wales and Northern Ireland to access the first licensed treatment for moderate-to-severe chronic kidney disease (CKD)-associated pruritus in adult patients on haemodialysis ST. GALLEN, Switzerland and STAMFORD, Conn., May 18, 2023 /PRNewswire/ — Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that … Read more

Kapruvia® (difelikefalin) recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

by

Recommendation will enable eligible patients in England, Wales and Northern Ireland to access the first licensed treatment for moderate-to-severe chronic kidney disease (CKD)-associated pruritus in adult patients on haemodialysis ST. GALLEN, Switzerland and STAMFORD, Conn., May 18, 2023 /PRNewswire/ — Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that … Read more